



Cytometry, Part A

DETECTION OF CFTR PROTEIN IN HUMAN LEUKOCYTES BY FLOW CYTOMETRY

Journal:	<i>Cytometry: Part A</i>
Manuscript ID:	13-160.R1
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Johansson, Jan; University of Verona, Pathology and Diagnostics Vezzalini, Marzia; University of Verona, Pathology and Diagnostics Verzè, Genny; University of Verona, Pathology and Diagnostics Caldrer, Sara; University of Verona, Pathology and Diagnostics Bolognin, Silvia; University of Verona, Department of Neurological and Movement Sciences, Section of Physiology Buffelli, Mario; University of Verona, Department of Neurological and Movement Sciences, Section of Physiology Bellisola, Giuseppe; Azienda Ospedaliera Universitaria Integrata di Verona, Department of Pathology and Diagnostics Tridello, Gloria; Azienda Ospedaliera Universitaria Integrata di Verona, Cystic Fibrosis Center Assael, Baroukh; Azienda Ospedaliera Universitaria Integrata di Verona, Cystic Fibrosis Center Melotti, Paola; Azienda Ospedaliera Universitaria Integrata di Verona, Cystic Fibrosis Center Sorio, Claudio; University of Verona, Pathology and Diagnostics
Key Words:	Leukocytes, Cystic fibrosis, chloride channel, biomarker

SCHOLARONE™
Manuscripts

TITLE

DETECTION OF CFTR PROTEIN IN HUMAN LEUKOCYTES BY FLOW CYTOMETRY

Jan Johansson^a, Marzia Vezzalini^a, Genny Verzè^a, Sara Caldrer^a, Silvia Bolognin^b, Mario Buffelli^b,
Giuseppe Bellisola^c, Gloria Tridello^d, Baroukh Maurice Assael^d, Paola Melotti^d and Claudio Sorio^{a*}

^a *Department of Pathology and Diagnostics, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy*

^b *Department of Neurological and Movement Sciences, Section of Physiology, University of Verona, Strada le Grazie 8, 37134 Verona-Italy.*

^c *Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale L. A. Scuro 10, 37134 Verona, Italy*

^d *Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Stefani 1, 37126, Verona, Italy*

* Corresponding author at: Department of Pathology and Diagnostics, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy. Tel. +39 045 8027688; fax +39 045 8027127. E-mail address: claudio.sorio@univr.it (C. Sorio).

Acknowledgments: This work has been supported by research grants issued by the Lega Italiana Fibrosi Cistica (Italian Cystic Fibrosis League) through Veneto Branch - Associazione Veneta Lotta contro la Fibrosi Cistica Onlus and by the Italian Cystic Fibrosis Research Foundation (Grants: FFC #5/2009, project adopted by the Rotary Club of Trentino Nord e Tomasi Gioielli; Trentino Branch - Associazione Trentina FC Onlus - in memory of Anita Furlini; FFC #6/2010, project adopted by Delegazione FFC di Verbania-Cusio Ossola, Trentino Branch - Associazione Trentina FC Onlus through the Gruppo di Sostegno FFC Trentino in memory of Silvia Somnavilla, Consorzio

1
2
3 Promotre s.c.r.l., Antonio Guadagnin and Sons, Alessandra Boccanera; FFC #26/2011, project
4
5 adopted by Donatori SMS Solidale 2011, Delegazione FFC di Varese, Associazione Trentina FC
6
7 onlus, FFC #6/2013, project adopted by Delegazione FFC di Minerbe Verona, Delegazione FFC di
8
9 Imola e Romagna).

10
11
12
13
14 Conflict of interest: The authors have no conflict of interest to disclose
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

ABSTRACT

Background: Leukocytes have previously been shown to express detectable levels of the protein Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). This study aims to evaluate the application of flow cytometry analysis to detect CFTR expression, and changes thereof, in these cells.

Methods: Aliquots (200 μ L) of peripheral whole blood from; 12 healthy control volunteers (CTRLs), 12 carriers of a *CFTR* mutation (CFC) and 40 cystic fibrosis (CF) patients carrying various combinations of *CFTR* mutations, were incubated with specific fluorescent probes recognizing CFTR protein expressed on the plasma membrane of leukocytes. Flow cytometry was applied to analyze CFTR expression in monocytes, lymphocytes and in polymorphonuclear (PMN) cells.

Results: CFTR protein was detected in monocytes and lymphocytes whereas inconclusive results were obtained from analysis of PMN cells. MFI ratio value and %CFTR positive cells above a selected threshold were the two parameters selected to quantify CFTR expression in cells. Lowest variability and the highest reproducibility were obtained when analysing monocytes. ANOVA results indicated that both parameters were able to discriminate monocytes of healthy controls and CF individuals according to *CFTR* mutation classes with high accuracy. Significantly increased MFI ratio values were recorded in CFTR-defective cells that were able to improve also CFTR function after *ex vivo* treatment with PTC124 (Ataluren), an investigative drug designed to permit the ribosome to read-through nonsense *CFTR* mutations.

Conclusions: The method described is minimally invasive and may be used in the monitoring of responses to drugs whose efficacy can depend on increased CFTR protein expression levels.

Key words

1
2
3 Cystic Fibrosis

4
5 Leukocytes

6
7 cystic fibrosis transmembrane conductance regulator (CFTR)

8
9 Genetic disease

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

INTRODUCTION

Cystic fibrosis (CF) is the most common recessively inherited disease among caucasians [1]. The affected gene encodes the protein Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which functions as an anion channel in epithelial cells. Since its discovery in 1989, biomedical research has focused on targeting the underlying genetic defect to identify a disease-modifying therapy for CF patients. Over 1,900 mutations identified in the *CFTR* gene have been clustered in 5 major classes (available at <http://www.genet.sickkids.on.ca/cftr/>). Class I mutations impair CFTR protein synthesis, no CFTR protein reaches the plasma membrane and chloride transport through CFTR does not occur. Class II mutations cause subcellular mislocalization and rapid degradation of CFTR. The little CFTR protein that reaches plasma membrane often does not function properly. In class III and IV mutations CFTR is expressed on the plasma membrane but the chloride transport is impaired. Class V mutations have both reduced CFTR synthesis and a reduced number of CFTR channels that transport chloride through the plasma membrane appropriately [2]. A dysfunction of CFTR anion channel in epithelial cells is thought to be the main cause for hyperviscous mucus production, infections and inflammation in CF patients' lungs. However, excessive neutrophil accumulation in the lung is also a hallmark of CF disease and altered leukocyte functions have also been hypothesized to significantly contribute to the pathogenesis of the disease. Several data support this vision. Already back in 1991 Yoshimura et al. [3] demonstrated mRNA encoding for CFTR in human leukocytes, but not until recently CFTR protein was detected in neutrophils [4,5], in lymphocytes [6,7] and in monocytes [8,9], in which it was shown to be involved in membrane potential regulation [8]. Monocytes can differentiate into macrophages and possible roles of CFTR in those cells include involvement in inflammation [10] and in bactericidal activities [11,12].

Class I mutations represent approximately 10% of total CFTR mutations associated with CF disease in patients worldwide [13]. In CF patients with this class of mutations the presence of a premature stop codon causes the translation of mRNA to cease prematurely. The resulting truncated CFTR

1
2
3 protein does not reach the cell membrane causing a severe impairment of chloride transport in
4
5 epithelial cells. When exposed to corrector drugs, designed to overcome the defective codon
6
7 readthrough by ribosomes, increased CFTR protein synthesis can be expected in cells. To test the
8
9 efficacy of those drugs, variations of CFTR expression levels in easily accessible cells like
10
11 peripheral blood leukocytes would be valuable. Semi-quantitative information on CFTR expression
12
13 levels, as well as data of the molecular mass of detected proteins, can be obtained by western blot
14
15 (WB). Nevertheless, this technique has limited utility in a monitoring program of CF patients due to
16
17 complex processing of the sample and the relatively great amounts of biological material necessary
18
19 to perform the analysis. On the contrary, flow cytometry (FC) analysis of cells performed on a few
20
21 hundred microliters of peripheral blood may represent a very sensitive technique useful to quantify
22
23 the relative number of CFTR molecules expressed in representative cells as well as their variations.
24
25 The aim of this study is to evaluate the potential use of FC analysis in detecting the presence and in
26
27 measuring relative CFTR protein levels in leukocytes. To our knowledge, only one study has
28
29 recently analyzed the expression of CFTR in peripheral blood leukocytes by flow cytometry [9].
30
31 However, lymphocytes were not studied and CFTR expression was investigated only in a few
32
33 individuals. In order to test a setting closer to clinical applications we first evaluated the presence of
34
35 CFTR in peripheral blood mononuclear cells (PBMCs). We then optimized two FC parameters for
36
37 the comparison of CFTR expression levels in major leukocyte sub-populations in peripheral blood
38
39 samples from groups of at least five CF patients representing the most frequent *CFTR* mutation
40
41 classes. Moreover, we tested the sensitivity of FC parameters by analysing variations of CFTR
42
43 expression levels induced by exposing monocytes from CF patients with nonsense mutation
44
45 genotype to PTC124 (Ataluren), a drug able to promote the expression of CFTR in a CF mouse
46
47 model with a CFTR-G542X nonsense mutation [14] and that is under clinical evaluation in a phase
48
49 III study. The results of FC analysis were related to those of a CFTR functional assay performed in
50
51 parallel on replicate samples from the same CF patients.
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Patients

Forty CF patients were grouped according to the class of CFTR mutations [2]. The control group (CTRL) consisted of 12 individuals selected among healthy volunteers. Additional control subjects included 12 healthy CF carriers (CFC), i.e. patients' parents, with one mutated *CFTR* allele. Details about CFC and CF patients are shown in **Table 1**. Samples and data were used for analysis only after informed consent was obtained according to guidelines approved by the local Ethical Committee.

Detection of biotinylated CFTR in peripheral blood mononuclear cells (PBMCs)

Roughly 4×10^7 PBMCs recovered from 25 mL buffy-coat samples were obtained by centrifugation on Ficoll gradient (GE Healthcare, Piscataway, USA). Cells were washed and then incubated for 30 minutes at +4°C with 2mM EZ-link® sulfo-NHS-biotin (Pierce Biotechnology, Rockford, U.S.A.). Excess biotin was removed by three washes with PBS containing 100mM glycine. Total cell proteins were extracted as described previously [8]. A quantity of 65 µg total proteins was immunoprecipitated using protein G sepharose (GE Healthcare, Piscataway, USA) and either of two different rabbit anti-CFTR antibodies (Alomone Labs, Jerusalem, Israel and Santa Cruz Biotechnology, Dallas, U.S.A.) recognizing the C- and N-terminus of CFTR, respectively. Either of two other different rabbit antibodies were utilized to control both efficiency and specificity of the immunoprecipitation procedure. Immunoprecipitates were denatured for 20 minutes at 40°C in Laemmli sample buffer, separated on a 6% acrylamide/bisacrylamide gel and transferred onto nitrocellulose membrane (GE Healthcare, Piscataway, U.S.A.). Membranes were washed, blocked and then incubated with 40 ng/mL HRP-conjugated streptavidin (Jackson ImmunoResearch Laboratories, West Grove, U.S.A.), which binds to biotinylated proteins. Signal was detected on nitrocellulose membrane by the HRP-catalyzed ECL method (Millipore, Billerica, U.S.A.).

Immunofluorescence labelling of leukocytes

Aliquots of 100 μL peripheral blood were used for FC analysis within five hours after blood withdrawal. Red blood cells were lysed in 1 mL solution containing: 0.89% (w/v) NH_4Cl , 0.10% (w/v) KHCO_3 and 200 μM EDTA. After addition of 5% FBS in PBS, samples were centrifuged for 7 min at 300xg at room temperature, the supernatant was reduced to a volume of 100 μL and 10 μL human serum (Sigma-Aldrich, Missouri, U.S.A.) was added. Cells were incubated with a mouse anti-CD14 antibody conjugated with the tandem fluorophores PE-Cy7($\lambda_{\text{nm}} = 488_{\text{ex}}/750_{\text{em}}$) or with allophycocyanin (APC) fluorochrome ($\lambda_{\text{nm}} = 635_{\text{ex}}/670_{\text{em}}$) according to manufacturer (BioLegend, San Diego, U.S.A. and Miltenyi Biotec, Germany, respectively). Washed cells were fixed for 20 minutes at room temperature in 0.5 mL Fixation buffer (BioLegend, San Diego, U.S.A.). After treatment with Permeabilization Wash Buffer (PWB) according to manufacturer (BioLegend, San Diego, U.S.A.), cells were incubated (45 min at room temperature) with primary antibody (polyclonal rabbit anti-CFTR Alomone Labs, Jerusalem, Israel, 800 ng or 150 ng/100 μL blood sample from lot numbers 04 and 05, respectively). To decrease non specific binding, human serum (10% v/v) was added to sample before its incubation with primary antibody. To measure the contribution of non specific antibody-cell interactions the rabbit polyclonal primary antibody was pre-incubated with a blocking peptide (4 μg) corresponding to aminoacids 1468-1480 in the C-terminal domain of CFTR. A mouse monoclonal anti-CFTR antibody, clone 13-1 (1.2 $\mu\text{g}/\text{sample}$) from R&D System, Minneapolis, U.S.A., was used in some replicate samples. This monoclonal antibody recognizes an epitope on the R-domain of CFTR. Goat anti-Rabbit IgG antibody (1.5 $\mu\text{g}/\text{sample}$) conjugated with Alexa Fluor (AF) 488 (Life Technologies, Carlsbad, U.S.A.) or Rabbit F(ab')₂ anti-Mouse Ig antibody (300 ng/sample) conjugated with FITC (DAKO, Glostrup, Denmark) were used as secondary antibodies.

Flow cytometric (FC) analysis of CFTR expression in leukocytes and effect of PTC124

1
2
3 Fluorescence, forward and side scatters were determined in cells using a MACSQuant Analyser
4 (Miltenyi Biotech, Cologne, Germany) processing 80000 total events and performing statistics of
5 roughly 2000 monocytes with FCS Express v3 software (De Novo Software, Los Angeles, U.S.A.).
6
7 Granulocyte, lymphocyte and CD14 positive monocyte cell populations were identified and gated
8
9 by visual inspection of dot plots using side scatter values versus CD14/PE-Cy7 fluorescence values.
10
11 A threshold value (background) was determined in sample stained with rabbit polyclonal anti-CFTR
12 antibodies pre-incubated with blocking peptide. The percentage of events above the threshold
13 corresponded to background noise. The percentage of CFTR positive cells (%CFTR positive cells)
14 was calculated as the difference between the percentage above the threshold obtained without
15 blocking peptide and background noise. The ratio between Mean Fluorescence Intensity (MFI)
16 values in samples processed with and without blocking peptide was related to CFTR expression
17 levels in cells. Average MFI ratio values and average %CFTR positive cells values were used to
18 compare different groups of individuals.
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Flow cytometric analysis of CFTR expression levels was performed using also enriched
33 monocytes (>70% purity) from 6 CF patients carrying a *CFTR* nonsense mutation. Results obtained
34 from monocytes exposed *ex vivo* for 24 hours to 10 μ M PTC124 (Selleckchem, Houston, U.S.A.)
35 were compared to untreated controls (CTRL). This small-molecular agent has been designed by
36 PTC Therapeutics to make ribosomes less sensitive to premature stop codons. Fixed cells were
37 stained using the polyclonal rabbit anti-CFTR antibody, as described above. A total of 10.000
38 events corresponding to purified cells were registered and analysed for CFTR expression levels.
39
40
41
42
43
44
45
46
47
48

49 ***Functional CFTR assay***

50
51
52 CFTR function was tested by imaging cell membrane potential of adherent monocytes using
53 the probe bis-(1,3-diethylthiobarbituric acid) trimethine oxonol (DiSBAC₂(3), Life Technologies,
54 Carlsbad, U.S.A.), as previously described [8]. In this assay, CFTR function is expressed by a CF
55
56
57
58
59
60

1
2
3 index, which has positive values when CFTR anion channel functions properly and negative values
4
5 when its ability to transport chloride anions through plasma membrane is reduced or absent.
6
7

8 9 *Sub-cellular localization and quantification of CFTR by confocal microscopy*

10 To localize the cellular distribution of fluorescent probes corresponding to CFTR and CD14
11 molecules, leukocytes already labelled with antibodies as described above were stained also with
12 3 μ M DAPI (Sigma-Aldrich, Missouri, U.S.A.). Cells were plated onto microscopy slides, dried and
13 cover slip was added with anti-fading mounting medium. They were then analysed with a Leica
14 TCS-SP5 confocal microscope (Leica Microsystem, Wetzlar, Germany). Wavelengths were the
15 same as those selected in flow cytometric studies whereas for DAPI the following wavelengths
16 were used: $\lambda_{nm} = 360_{ex}/460_{em}$. Z-stack images were merged to quantify CFTR signal in cells. Gray
17 scales of 32-bit TIFF images were measured with ImageJ ver 1.43u. Around 10 cells/sample were
18 analysed and background values were subtracted. Mean values of cells from each CF patient and
19 each healthy CTRL donor were used to compare the two groups.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Statistics*

37
38 SigmaStat software version 3.0 (SPSS Inc., Chicago, U.S.A.) was used for statistical
39 calculations. According to the distribution of results, parametric and/or nonparametric statistics
40 were applied to test hypotheses on the means and/or the medians. The α value was set to 0.05 and
41 the level of significant difference to $P < 0.05$.
42
43
44
45
46
47
48

49 **RESULTS**

50 51 52 53 *Cell membrane localization of CFTR in peripheral blood mononuclear cells*

54
55
56 CFTR expression in non CFTR-defective PBMCs is illustrated in **Figure 1**. Two different forms
57 of biotinylated CFTR (lanes 2 and 4) were immunoprecipitated (IP) by either of two rabbit anti-
58
59
60

1
2
3 CFTR antibodies recognizing the C-terminus or N-terminus of CFTR. The two antibodies may have
4
5 different IP efficiency, as suggested by the different signal intensities of common bands detected at
6
7 around 150 and 180 kDa. The specificity of the result is suggested by the absence of bands in the
8
9 same sample immunoprecipitated with either of two non CFTR-related rabbit polyclonal antibodies
10
11 (**Figure 1**, lanes 1 and 3). **Figure 2** shows the different expression of CFTR in leukocytes from
12
13 healthy CTRLs (A-D) and from two CF patients with genotypes R1158X/E585X (E-G), and
14
15 W1282X/F508del (H). Leukocytes were stained with rabbit polyclonal anti-CFTR antibody
16
17 (**Figures 2D and H**) or with mouse monoclonal anti-CFTR antibody (**Figures 2B and F**) and anti-
18
19 CD14 antibody (**Figures 2A and E**). A partial co-localization of CFTR and CD14 on monocyte
20
21 plasma membrane is shown in **Figure 2C**. A more intense green fluorescence, corresponding to
22
23 CFTR staining, was observed in monocytes from healthy CTRLs (**Figures 2B and D**) than in
24
25 monocytes from CF patients (**Figures 2F and H**) whereas the red fluorescence intensity of CD14
26
27 staining is similar in monocytes of CTRLs and CF patients. This was observed in results obtained
28
29 by the polyclonal as well as by the monoclonal antibodies. Histogram in Figure 2 summarize the
30
31 quantification data of CFTR signal in cells from three healthy CTRL donors and from three CF
32
33 patients. A paired t-test revealed a significant difference between the mean values of the two groups
34
35 ($P=0.018$).
36
37
38
39
40
41
42

43 ***Setting parameters for FC analysis of whole blood samples: MFI ratio and percent of CFTR***
44 ***positive cells***
45

46
47 **Figure 3** illustrates how sub-cellular populations of CFTR positive leukocytes were identified
48
49 by FC analysis in two whole peripheral blood samples stained with anti-CD14 and with polyclonal
50
51 rabbit anti-CFTR antibodies. A sub-population of CD14 positive cells, different from lymphocytes
52
53 and granulocytes that stained very weakly with anti-CD14 antibody, can be easily distinguished
54
55 plotting side scatter versus PE-Cy7 fluorescence intensity values (**Figure 3A**). This highly CD14
56
57 positive sub-population with relatively low side scatter values was assigned to monocytes. **Figures**
58
59
60

1
2
3 **3B and D** illustrate the positioning of thresholds for CFTR positivity in monocytes from a healthy
4 CTRL (**Figure 3B**) and from a CF patient (**Figure 3D**) homozygous for a class I *CFTR* mutation
5 (R1162X). In the presence of blocking peptide (**Figures 3B and D**) less than 10% CTRL and CF
6 monocytes incubated with rabbit polyclonal anti-CFTR antibody had AF488 fluorescence detected
7 above the threshold. Without blocking peptide (**Figures 3C and E**) those percentages increased to
8 about 80% in monocytes from healthy CTRL (**Figure 3C**) and only to about 40% in monocytes
9 from CF patient (**Figure 3E**). Thresholds positioned in the same way were utilized to distinguish
10 CFTR expression from the background noise in lymphocytes. The ratio between MFI value of the
11 replicate sample processed without blocking peptide and the MFI value of the corresponding
12 replicate sample processed with blocking peptide reflected CFTR expression in sub-populations of
13 leukocytes being analysed.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 ***Reproducibility and robustness of FC analysis***

31
32 The same operator labelled and analyzed different blood withdrawals from the same subject to
33 test the repeatability of the FC analysis. **Table 2** summarizes the different test conditions and
34 results. Intraindividual biological and technical (eg. different batches of reagents) variabilities were
35 tested by separately analysing blood withdrawals, obtained within a period of two years, from two
36 subjects. Samples from one of these subjects (number 2, **Table 2**) were also analysed frequently
37 during this period, and results obtained with either of two different anti- CFTR antibody batches
38 (lots 04 and 05) are presented in order to highlight the contribution of this parameter to the overall
39 variability. The within-day repeatability was tested twice (Day A and Day B, **Table 2**) by
40 performing the labelling and analysis in parallel of four replicates using the same blood sample and
41 the same reagents. The analytical variability decreased significantly when testing the within-day
42 repeatability, as shown by the coefficient of variation (CV) of MFI ratio values (**Table 2**) resulting
43 1.6% and 2.8% in the two tests performed, respectively.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 To test the reproducibility of the FC test, blood samples from the same subject were labelled
4 and analyzed repeatedly (n=6) during a period of ten months by two operators not working in
5 parallel. Operator 1, who performed the tests of repeatability above, obtained the following results;
6 (MFI ratio: mean = 1.88, CV = 11.0% and %CFTR positive monocytes: mean = 84.2, CV = 5.8%)
7 Operator 2, who performed this FC analysis less frequently, obtained the following results; (MFI
8 ratio: mean = 2.11, CV = 17.3% and %CFTR positive monocytes: mean = 82.0, CV = 12.6%).
9
10
11
12
13
14
15

16 To test how robust the FC analysis was, a comparison was performed on mean values
17 (mean±SD) of MFI ratio and of %CFTR positive monocytes in blood samples from healthy CTRLs,
18 from CFC healthy individuals and from CF patients. Patients were grouped according to their
19 membership in four different *CFTR* mutation classes: I+I (n = 12), I+II (n = 12), II+II (n = 11), and
20 I+V (n = 5). ANOVA analysis was followed with Holm-Sidak method and the results, summarized
21 in **Figure 4**, show that monocytes of all CF patient groups had significantly lower average MFI
22 ratio values than monocytes of healthy CTRLs. Average MFI ratio value was significantly lower in
23 monocytes of CF patients with class I mutations on both alleles (**Figure 4 A**, I+I) than in
24 monocytes of healthy CFC individuals, but no significant difference was observed among groups of
25 CF patients or between healthy CTRLs and healthy CFC individuals. It may be noted that
26 interindividual variability, as indicated by CV%, was comparable among groups and also
27 comparable to the intraindividual variability shown in **Table 2**. On the contrary, greater variability
28 was observed among values indicating %CFTR positive monocytes in some groups, as shown in
29 **Figure 4 B**. Nevertheless, the results of Holm-Sidak method indicated that mean values of %CFTR
30 positive monocytes were significantly different in the group of healthy CTRLs, or in the group of
31 CFC individuals, and groups of CF patients, but differences were also observed among some CF
32 groups as indicated in **Figure 4 B**.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 MFI ratio values reflecting CFTR expression in lymphocytes were not normally distributed and
54 significant differences identified among groups by Kruskal-Wallis ANOVA on ranks (P = 0.003)
55 were not further indicated by multiple pair-wise comparisons performed with Dunn's method. The
56
57
58
59
60

1
2
3 %CFTR positive lymphocyte mean values resulted significantly different among groups (ANOVA
4
5 $P < 0.03$). In this case, pairs-wise comparison by Holm-Sidak method identified differences between;
6
7 healthy CTRLs (38.9 ± 13.3) and class I+II CF patients (16.0 ± 12.8 , $P = 0.004$), CFC individuals
8
9 (26.7 ± 19.2) and class II+II CF patients (45.4 ± 21.9). Class I+II CF patients with the lowest average
10
11 %CFTR positive lymphocyte values resulted significantly different also from classes II+II
12
13 ($P < 0.001$), I+I (32.2 ± 19.1 , $P = 0.004$) and I+V (42.8 ± 17.8 , $P = 0.004$) CF patients.
14
15

16
17 However, the high CV% values ranging from 34% in CTRLs to 80% in the class I+II group
18
19 reflect an important contribution of interindividual variability when %CFTR positive lymphocytes
20
21 were compared.
22
23

24 25 ***Detection of drug-induced CFTR expression variations in monocytes by FC analysis*** 26

27
28 Type I mutations are expected to severely impair CFTR expression in CF patients. The CFTR
29
30 corrector PTC124 (Ataluren) is currently under clinical evaluation for its potential to restore CFTR
31
32 protein expression and function as chloride channel. In order to properly associate the results of FC
33
34 analysis to a genuine drug response, FC analysis and a CFTR functional assay were performed in
35
36 replicate samples of monocytes from 6 CF patients with different CFTR genotypes (all including a
37
38 CFTR nonsense mutation) by two researchers unaware of the other's results. The results are
39
40 summarized in **Table 3**. In monocytes from patients #1 and #2, exposed *ex vivo* for 24 hours to
41
42 $10 \mu\text{M}$ PTC124, the MFI ratio values increased 25% and 12%, respectively, as compared to control
43
44 samples (0.1% DMSO in cell culture medium). These variations are greater than those measured in
45
46 within-day replicates (CV% $< 3\%$, see above and **Table 2**). Functional assay run in parallel showed
47
48 a recovery of CFTR function in the same samples. In monocytes from the remaining four patients
49
50 CFTR expression levels were unchanged (differences between treated and untreated samples were
51
52 lower than 3%). Interestingly, we did not detect any improvement of CFTR function either in these
53
54 same four samples exposed to PTC124.
55
56
57
58
59
60

DISCUSSION

There is increasing evidence that myeloid cells may play an important role in the pathogenesis of CF [15]. Therefore, the measurement of CFTR expression in easily accessible peripheral blood leukocytes has important implications, not only as surrogate biomarker but also as a way to monitor the correction of the defect in cells that are key players in CF. This monitoring may be of particular importance because drugs targeting defective CFTR are already available and others are in advanced stages of clinical evaluations for the therapy of CF patients [16]. Different methods to evaluate the effects of CFTR corrector drugs in patients suffer from some objective limitations and the availability of a reproducible analytical method capable of detecting CFTR expression in human leukocytes might represent an important advance in this context.

The localization of CFTR protein on the plasma membrane of peripheral blood leukocytes was verified by a cell surface protein biotinylation approach of intact cells. Combining immunoprecipitation, gel electrophoresis and streptavidin detection of biotinylated proteins we revealed a band at around 150 kDa that was thicker than that at around 180 kDa, which is the predicted molecular mass of fully glycosylated and mature form of the CFTR protein (**Figure 1, lanes 2 and 4**). This 150 kDa band may represent both the product of a partial degradation of the CFTR protein during or after the biotinylation process as well as a differentially processed form of CFTR, as indicated previously [8]. A role of calpain in the turnover of membrane bound CFTR has already been suggested in PBMCs [17]. However, relative masses described for calpain-derived CFTR fragments were 70 kDa and 100 kDa, respectively. Therefore the 150 kDa band should not represent the product of CFTR digestion by calpain. CFTR protein partially co-localizes with CD14 antigen on the plasma membrane of monocytes as revealed by confocal microscopy studies. Therefore we set conditions to detect CFTR expression in peripheral blood leukocytes by flow cytometry. While we could detect fluorescence related to CFTR expressed in monocytes and lymphocytes, the possibility to detect a specific CFTR signal in granulocytes was precluded in our study, probably because the permeabilization of plasma membrane induced high levels of auto-

1
2
3 fluorescence in those cells (data not shown). Granulocytes, which represent the most abundant cell
4
5 population in peripheral blood, have been reported to express CFTR [4,5]. However, altered CFTR
6
7 protein expression levels in neutrophils have been related to inflammation [4]. Also absent CFTR
8
9 expression as detected by FC in neutrophils has been reported [9], but low signal to noise ratio
10
11 values might not have been properly considered and the contribution of high MFI values obtained
12
13 with an isotype control antibody may have been underestimated. When we analysed CFTR
14
15 expression in lymphocytes, the second largest sub-population of leukocytes in peripheral blood
16
17 samples, we noticed low autofluorescence after cell permeabilization making lymphocytes more
18
19 suitable than granulocytes for CFTR expression analysis by FC. Moreover, some significant
20
21 differences could be observed comparing MFI ratio values and the percentages of CFTR positive
22
23 lymphocytes among groups. Unfortunately, those results were strongly influenced by a high degree
24
25 of variability, possibly related to different CFTR expression in lymphocyte sub-populations (e.g. B-
26
27 and T-cells). Specific biomarkers can be used to separate cell sub-populations, but they both impact
28
29 the costs of the test and increase the complexity of interpretation of the results. Therefore, we
30
31 focused on the optimization of MFI ratio values and %CFTR positivity in monocytes that, in our
32
33 hands, represented the most suitable leukocyte sub-population for FC analysis of CFTR expression
34
35 in peripheral blood.
36
37
38
39

40
41 Both analytical and biological variability contributes to the results of ANOVA performed to
42
43 distinguish differences among groups of CF patients, healthy CFC and healthy CTRL individuals
44
45 according to the levels of CFTR expression in monocytes. In order to limit analytical variability we
46
47 pre-incubated the primary antibody with a blocking peptide instead of using an isotype control
48
49 antibody to calculate MFI ratio values. In this way we reduced the experimental variability, for
50
51 instance caused by use of different antibody lots or by stability over time of fluorescent probes
52
53 ensuring that significant differences identified by ANOVA preferentially reflected biological rather
54
55 than analytical variability. The MFI ratio values of CFTR staining in monocytes showed lower
56
57 variability as compared to those indicating %CFTR positive monocytes, as suggested by the values
58
59
60

1
2
3 of CV% (**Figure 4**). This may be partially explained by the adjustment of the threshold value that is
4 necessarily set experimentally during the analytic phase of the assay. Small changes of this
5 threshold (between 5 to 10% of gated events) negatively impact on the results of the statistical
6 analysis when groups of samples from different individuals are considered.
7
8
9

10
11 We further wanted to test the capability of FC analysis to detect changes of CFTR expression
12 levels in monocytes exposed *ex vivo* to PTC124 (Ataluren), a CFTR corrector under evaluation in
13 clinical trials. As compared to untreated controls, monocytes exposed to PTC124 showed variations
14 greater than those of within-day repeatability in samples from patients #1 and #2, thus suggesting
15 that FC analysis in monocytes can be a useful method to monitor variations of CFTR expression
16 levels related to drug treatment. Monocytes from the same blood sample showed a significantly
17 increased CFTR function after exposure to PTC124, thus proving that the response to the drug
18 measured by FC was reflecting a true recovery of CFTR expression on the cell membrane. This
19 result interpretation was further supported by the evidence that the variations of CFTR expression in
20 monocytes from patients # 3-6 were similar to the within-day repeatability of controls (1-2%) and
21 that the results of the functional CFTR assay performed on the same samples documented the
22 inability of PCT124 to induce any significant improvement of CFTR activity in those four samples.
23
24 It is still not clear whether the responses to protein translation correctors might be influenced by an
25 individual capability of ensuring a proper drug mediated read-through of the mutation by the
26 translation machinery. A possible explanation of the absence of PTC124 effects in four cases out of
27 six may be an absence of substrate due to an increased degradation of mRNA containing a
28 premature stop codon, as discussed by Linde and Kerem [18]. Being the patients heterozygous for a
29 nonsense mutation, another possible influence might derive from the presence of the second
30 mutation that might impact on the capability to respond to the treatment. Variability of responses to
31 drugs in cells and patients are common occurrence and the observed concordance between
32 expression and the functional assays allows us to conclude that FC analysis might represent a
33 powerful approach for the evaluation of responses to drugs targeting specific basic defects in CF
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 leukocytes. However, we realize that the robustness of this analytical approach must be confirmed
4
5 in a greater number of observations either *ex vivo* or *in vivo* before proposing its use in the follow-
6
7 up of CF patients.
8

9
10 In conclusion, we have described a relatively simple method to test CFTR expression in
11
12 leukocytes starting from a few milliliters of peripheral blood that can be easily obtained from
13
14 patients without too much discomfort. Once validated, the test might represent a convenient
15
16 approach for the monitoring of selected therapies in CF patients.
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

- [1] Lubamba B, Thooghe B, Noel S, Leal T. Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. *Clin Biochem* 2013; 45: 1132-1144
- [2] Zielenski J, Tsui L-C. Cystic fibrosis: genotypic and phenotypic variations. *Annu Rev Genetics* 1995;29:777-807
- [3] Yoshimura K, Nakamura H, Trapnell BC, Chu C-S, Dalemans W, Pavirani A, Lecocq J-P, Crystal RG. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. *Nucl Acid Res* 1991; 19: 5417-5423
- [4] Su X, Looney MR, Su H, Lee JW, Song Y, Matthay MA. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. *Inflamm Res* 2011; 60: 619-632
- [5] Painter RG, Valentie VG, Lanson Jr NA, Leidal K, Zhang Q, Lombard G, Thompson C, Viswanathan A, Nauseef WM, Wang G, Wang G. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. *Biochem* 2006; 45: 10260-10269
- [6] Averna M, Stifanese R, Grosso R, Pedrazzi M, De Tullio R, Salamino F, Pontremoli S, Melloni E. Role of calpain in the regulation of CFTR (cystic fibrosis transmembrane conductance regulator) turnover. *Biochem J* 2010; 430: 255-263
- [7] Shanshiashvili LV, Dabrundashvili N, Natsvilishvili N, Kvaratskhelia E, Zhuravliova E, Barbakadze T, Koriauli S, Maisuradze E, Topuria T, Mikeladze DG. mGluR1 interacts with

- 1
2
3 cystic fibrosis transmembrane conductance regulator and modulates the secretion of IL-10 in
4
5 cystic fibrosis peripheral lymphocytes. *Mol Immunol* 2012; 51: 310-315
6
7
8
- 9
10 [8] Sorio C, Buffelli M, Angiari C, Ettore M, Johansson J, Vezzalini M, Viviani L, Ricciardi M,
11
12 Verzè G, Assael BM, Melotti P. Detective CFTR expression and function are detectable in
13
14 blood monocytes: development of a new blood test for cystic fibrosis. *Plosone* 2011; 6: 1-13
15
16
17
- 18
19 [9] Van de Weert-van Leeuwen PB, Van Meegen MA, Speirs JJ, Pals DJ, Rooijackers SH, Van der
20
21 Ent CK, Terheggen-Lagro SW, Arets HG, Beekman JM. Optimal complement-mediated
22
23 phagocytosis of *Pseudomonas aeruginosa* by monocytes is CFTR-dependent. *Am J Resp Cell*
24
25 *Mol Biol* 2013; 49: 463-470
26
27
28
- 29
30 [10] Xu Y, Krause A, Hamai H, Harvey B-G, Worgall TS, Worgall S. Proinflammatory phenotype
31
32 and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. *Plosone* 2010;
33
34 5: 1-9
35
- 36
37 [11] Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas
38
39 V, Palfrey HC, Nelson DJ. CFTR regulates phagosome acidification in macrophages and
40
41 alters bactericidal activity. *Nature cell biol* 2006; 8: 933-944
42
43
44
- 45
46 [12] Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggò MA, Spadaio F, Guglietta S,
47
48 Anile M, Venuta F, Quattrucci S, Ascenzioni F. Dysfunctional CFTR alters the bactericidal
49
50 activity of human macrophages against *Pseudomonas aeruginosa*. *Plosone* 2011; 6: 1-8
51
52
53
- 54
55 [13] Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator
56
57 intracellular processing, trafficking, and opportunities for mutation-specific treatment. *Chest*
58
59 2011; 139: 1480–1490
60

- 1
2
3
4
5 [14] Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable
6
7 compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF
8
9 mouse model. *Proc Natl Acad Sci* 2008; 105: 2064-2069
10
11
12
13
14 [15] Bonfield TL, Hodges CA, Cotton CU, Drumm ML. Absence of the cystic fibrosis
15
16 transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation
17
18 and infection. *J Leukoc Biol* 2012; 92: 1111-1122
19
20
21
22
23 [16] Quintana-Gallego E, Delgado-Pecellín I, Calero Acuña C. CFTR Protein Repair Therapy in
24
25 Cystic Fibrosis. *Arch Bronconeumol*. 2013 Oct [Epub ahead of print]
26
27
28
29 [17] Averna M, Stifanese R, De Tullio R, Minicucci L, Cresta F, Palena S, Salamino F, Pontremoli
30
31 S, Melloni E. Evidence for alteration of calpain/calpastatin system in PBMC of cystic fibrosis
32
33 patients. *Biochim Biophys Acta* 2011; 1812: 1649-1657
34
35
36
37
38 [18] Linde L, Kerem B. Nonsense-mediated mRNA decay and cystic fibrosis. *Methods Mol Biol*
39
40 2011; 741: 137-154
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Fig. 1. Detection of CFTR in peripheral blood mononuclear cells (PBMCs). After biotinylation of intact PBMCs, protein extracts were immunoprecipitated with either of two different rabbit anti-CFTR antibodies recognizing the C-terminus (lane 2) or the N-terminus (lane 4) of CFTR and compared with samples incubated with either of two different rabbit control antibodies (lanes 1 and 3, respectively). Proteins separated on 6% acrylamide gel were transferred onto nitrocellulose membrane and biotinylated proteins were detected with HRP-conjugated streptavidin and ECL. In lanes 2 and 4, two bands detected at around 150 kDa and at 180 kDa were assigned to CFTR.

Fig. 2. Confocal analysis of CFTR expression in leukocytes.

Upper panel. Leukocytes from a healthy individual (A-C) and from a CF patient with genotype R1158X/E585X (E-G). A and E: cells stained with APC-conjugated anti-CD14 antibody, fixed and then stained in B and C with a mouse monoclonal (clone 13-1) anti-CFTR and FITC-conjugated secondary antibodies (B and F). Merged images are shown in C and G. The green fluorescence of a CFTR positive monocyte from a healthy CTRL individual is shown in B; a granulocyte and a CD14 positive monocyte are shown in E. Leukocytes from a healthy CTRL in D and from a CF patient (genotype W1282X/F508del) in H were stained with a polyclonal rabbit anti-CFTR antibody and detected with an AF488-conjugated secondary antibody. Nuclei were stained with DAPI (blue) and shown in all images, except in B and in F. Scale bar = 10 μ m.

Lower panel: Quantification of fluorescence signals in cells from healthy CTRL donors and from CF patients (two patients with I+I and one patient with I+II mutation classes). Bars are means \pm S.E.M., paired t-test, P=0.018, n=3.

Fig. 3. Flow cytometry analysis of dot-plot graphs of human leukocytes in whole blood samples of healthy CTRLs. A. The separation of granulocytes, monocytes and lymphocytes sub-populations by

1
2
3 plotting side scatter vs. fluorescence emitted by PE-Cy7 fluorochromes (CD14, monocytes).
4
5 Forward scatter values of gated monocytes from a healthy CTRL (B and C) and a CF patient with
6
7 genotype R1162X/R1162X (D and E) plotted vs CFTR protein signal detected in green channel by
8
9 AF488 fluorochrome. The threshold of CFTR-signal (red line) was set to obtain 90-98% total
10
11 monocytes, stained with anti-CFTR antibody pre-incubated with blocking peptide, below the value
12
13 (B and D). Cells stained with anti-CFTR antibody without blocking peptide are shown in C and E,
14
15 respectively. To calculate the percentage of CFTR positive monocytes the values in B (or in D)
16
17 were subtracted from values in C (or in E), respectively (eg. $83.4 - 5.0 = 78.4\%$).
18
19
20
21
22

23 Fig. 4. FC analysis of CFTR expression data in monocytes. Box and whisker plots (25th-75th
24
25 percentiles) of MFI ratio values (A) and percent CFTR positive monocyte values (B) in healthy
26
27 controls (CTRLs), healthy CF carriers (CFC) and cystic fibrosis (CF) patients grouped according to
28
29 *CFTR* mutation class (I, II and V) being carried. The midline in boxes indicates median and
30
31 whiskers represent the lowest and highest values, respectively. Symbols indicate significant
32
33 differences (* $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$) identified by Holm-Sidak method used to
34
35 compare means of pairwise groups.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Subjects with known genotype enrolled in the study.

#	Mutation class	Gender	Age (years)	G e n o t y p e	
Healthy carriers of a CFTR mutation (CFC)					
1	I	F	48	WT	G542X
2	I	F	39	WT	R1162X
3	I	M	47	WT	R1162X
4	I	F	44	WT	R1162X
5	I	F	62	WT	4013insT
6	I	F	61	WT	R1162X
7	I	F	58	WT	1717-1G>A
8	I	M	52	WT	2183AA>G
9	I	F	56	WT	R1162X
10	I	M	71	WT	W1282X
11	II	F	38	WT	F508del
12	II	F	46	WT	F508del
CF patients					
13	I + I	M	17	G542X	G542X
14	I + I	M	26	R1162X	R1162X
15	I + I	M	33	R1162X	R1162X
16	I + I	M	35	W1282X	621+1G>T
17	I + I	F	13	R1162X	R1162X
18	I + I	M	20	E585X	R1158X
19	I + I	F	44	R1162X	R1162X
20	I + I	F	25	G542X	R553X
21	I + I	F	36	Q552X	CFTRdele17a-18
22	I + I	M	37	G542X	CFTRdele1
23	I + I	M	31	Q552X	2183AA>G
24	I + I	M	12	R1162X	R1162X
25	I + II	M	18	Q39X	F508del
26	I + II	F	20	G542X	F508del
27	I + II	F	42	R1162X	F508del
28	I + II	F	23	R1162X	F508del
29	I + II	F	28	W57X	F508del
30	I + II	M	28	Q552X	F508del
31	I + II	M	14	R1162X	F508del
32	I + II	F	25	W1282X	F508del
33	I + II	M	11	G542X	F508del
34	I + II	M	16	Q552X	F508del
35	I + II	F	25	R1162X	F508del
36	I + II	F	23	R1162X	F508del
37	I + V	M	43	R1162X	3849+10kbC>T
38	I + V	F	32	R1162X	2789+5G>A
39	I + V	F	38	R1162X	3849+10kbC>T
40	I + V	M	46	G542X	3849+10kbC>T
41	I + V	F	24	R1162X	3849+10kbC>T

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

42	II + II	M	40	F508del	F508del
43	II + II	F	37	F508del	F508del
44	II + II	F	21	F508del	F508del
45	II + II	F	38	F508del	F508del
46	II + II	M	17	F508del	F508del
47	II + II	M	42	F508del	F508del
48	II + II	F	22	F508del	F508del
49	II + II	M	43	F508del	F508del
50	II + II	F	42	F508del	F508del
51	II + II	F	29	F508del	F508del
52	II + II	M	13	F508del	F508del

For Peer Review

Table 2.


	n	MFI ratio		%CFTR positive monocytes	
		Mean	CV	Mean	CV
Subject 1ⁱ (♀)	6	1.88	11.0%	84.2	5.8%
Subject 2ⁱ (♂)	6	1.95	13.1%	83.7	13.9%
Lot 04ⁱⁱ (♂)	21	2.13	21.7%	82.7	12.8%
Lot 05ⁱⁱ (♂)	36	1.82	10.3%	74.8	14.6%
Day Aⁱⁱⁱ (♂)	4	1.68	1.6%	62.8	10.5%
Day Bⁱⁱⁱ (♂)	4	1.64	2.8%	55.2	9.9%

Table 2. Repeatability of FC analysis of CFTR expression in monocytes. i) The same operator repeated FC analysis six times of samples from the same control individuals in different days; ii) between-day repeatability was tested by analyzing different samples from the same individual with either antibody Lot 04 or Lot 05; iii) within-day repeatability was tested by analyzing one sample four times on the same day and using the same antibody Lot.

Table 3.

ID #	Gender	Genotype	MFI before PTC124	MFI after PTC124	Variation (%CTRL)	CF index CTRL	CF index after PTC124	Variation (%)
1	F	<u>R1162X/</u> 3849+10kbC>T	1.47	1.84	+25	-41	+16	+57
2	M	<u>R553X/</u> D1152H	2.17	2.44	+12	-74	-33	+41
3	F	<u>R1162X/</u> N1303K	2.78	2.79	+1	-36	-32	4
4	M	<u>S466X/</u> R1070Q/ 1717-1G>A	1.76	1.72	-2	-2	-22	-20
5	M	<u>G542X/</u> 3849+10kbC>T	1.67	1.65	-1	-70	-95	-25
6	M	<u>Q552X/</u> 2183AA>G	2.24	2.28	+2	-25	-64	-39

Table 3. MFI ratio values and CF index variations induced in monocytes exposed *ex vivo* for 24 hours to 10 μ M PTC124 CFTR corrector or to 0.1% (v/v) DMSO (CTRL). Mutations being targets for PTC124 are underlined. CFTR expression levels and CFTR function reflected by MFI ratio and CF index values, respectively, were obtained by two researchers processing replicate samples of monocytes in parallel and unaware of the other's result. An increased CFTR function results in an increment of CF index value.





88x72mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



352x264mm (72 x 72 DPI)

Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



190x95mm (300 x 300 DPI)

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



161x76mm (300 x 300 DPI)

Table 1. Subjects with known genotype enrolled in the study.

#	Mutation class	Gender	Age (years)	G e n o t y p e	
Healthy carriers of a CFTR mutation (CFC)					
1	I	F	48	WT	G542X
2	I	F	39	WT	R1162X
3	I	M	47	WT	R1162X
4	I	F	44	WT	R1162X
5	I	F	62	WT	4013insT
6	I	F	61	WT	R1162X
7	I	F	58	WT	1717-1G>A
8	I	M	52	WT	2183AA>G
9	I	F	56	WT	R1162X
10	I	M	71	WT	W1282X
11	II	F	38	WT	F508del
12	II	F	46	WT	F508del
CF patients					
13	I/I	M	17	G542X	G542X
14	I/I	M	26	R1162X	R1162X
15	I/I	M	33	R1162X	R1162X
16	I/I	M	35	W1282X	621+1G>T
17	I/I	F	13	R1162X	R1162X
18	I/I	M	20	E585X	R1158X
19	I/I	F	44	R1162X	R1162X
20	I/I	F	25	G542X	R553X
21	I/I	F	36	Q552X	CFTRdele17a-18
22	I/I	M	37	G542X	CFTRdele1
23	I/I	M	31	Q552X	2183AA>G
24	I/I	M	12	R1162X	R1162X
25	I/II	M	18	Q39X	F508del
26	I/II	F	20	G542X	F508del
27	I/II	F	42	R1162X	F508del
28	I/II	F	23	R1162X	F508del
29	I/II	F	28	W57X	F508del
30	I/II	M	28	Q552X	F508del
31	I/II	M	14	R1162X	F508del
32	I/II	F	25	W1282X	F508del
33	I/II	M	11	G542X	F508del
34	I/II	M	16	Q552X	F508del
35	I/II	F	25	R1162X	F508del
36	I/II	F	23	R1162X	F508del
37	I/V	M	43	R1162X	3849+10kbC>T
38	I/V	F	32	R1162X	2789+5G>A
39	I/V	F	38	R1162X	3849+10kbC>T
40	I/V	M	46	G542X	3849+10kbC>T
41	I/V	F	24	R1162X	3849+10kbC>T
42	II/II	M	40	F508del	F508del
43	II/II	F	37	F508del	F508del

44	II / II	F	21	F508del	F508del
45	II / II	F	38	F508del	F508del
46	II / II	M	17	F508del	F508del
47	II / II	M	42	F508del	F508del
48	II / II	F	22	F508del	F508del
49	II / II	M	43	F508del	F508del
50	II / II	F	42	F508del	F508del
51	II / II	F	29	F508del	F508del
52	II / II	M	13	F508del	F508del

For Peer Review

Table 2.

	n	MFI ratio		%CFTR positive monocytes	
		Mean	CV	Mean	CV
Subject 1ⁱ (♀)	6	1.88	11.0%	84.2	5.8%
Subject 2ⁱ (♂)	6	1.95	13.1%	83.7	13.9%
Lot 04ⁱⁱ (♂)	21	2.13	21.7%	82.7	12.8%
Lot 05ⁱⁱ (♂)	36	1.82	10.3%	74.8	14.6%
Day Aⁱⁱⁱ (♂)	4	1.68	1.6%	62.8	10.5%
Day Bⁱⁱⁱ (♂)	4	1.64	2.8%	55.2	9.9%

Table 2. Reproducibility of FACS analysis of CFTR expression in monocytes. i) The same operator repeated 6 times FACS analysis on the same control individuals in different days; ii) within-days repeatability performed analyzing different samples from the same individual with either antibody Lots 04 or 05; iii) within-day repeatability performed analyzing one sample four times on the same day and using the same Lot of antibody.

Table 3.


ID #	Gender	Genotype	MFI before PTC124	MFI after PTC124	Variation (%CTRL)	CF index CTRL	CF index after PTC124	Variation (%)
1	F	<u>R1162X</u> / 3849+10kbC>T	1.47	1.84	+25	-41	+16	+57
2	M	<u>R553X</u> / D1152H	2.17	2.44	+12	-74	-33	+41
3	F	<u>R1162X</u> / N1303K	2.78	2.79	+1	-36	-32	4
4	M	<u>S466X</u> / <u>R1070Q</u> / 1717-1G>A	1.76	1.72	-2	-2	-22	-20
5	M	<u>G542X</u> / 3849+10kbC>T	1.67	1.65	-1	-70	-95	-25
6	M	<u>Q552X</u> / 2183AA>G	2.24	2.28	+2	-25	-64	-39

Table 3. MFI ratio values and CF index variations induced in monocytes exposed for 24 hours to 10 μ M PTC124 CFTR corrector or to 0.1% (v/v) DMSO (CTRL). Mutations being targets for PTC124 are underlined. CFTR expression levels and CFTR function reflected by MFI ratio and CF index values and were obtained by two researchers processing replicate samples of monocytes in parallel and unaware of the other's results, respectively. An increased CFTR function results in an increment of CF index value.

Cytometry Part A
Author Checklist: MIFlowCyt-Compliant Items

Requirement	Please Include Requested Information
1.1. Purpose	Test CFTR expression in human leukocytes and specificity of anti-CFTR antibody
1.2. Keywords	CFTR human leukocytes flow cytometry
1.3. Experiment variables	Biological samples from different human individuals
1.4. Organization name and address	Department of Pathology and Diagnostics, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy
1.5. Primary contact name and email address	Claudio Sorio, claudio.sorio@univr.it
1.6. Date or time period of experiment	2011-2013
1.7. Conclusions	A specific signal of CFTR expression was observed in monocytes and lymphocytes, but not in granulocytes
1.8. Quality control measures	Instrument calibrations with beads were performed
2.1.1.1. (2.1.2.1., 2.1.3.1.) Sample description	Human samples with known <i>CFTR</i> genotypes
2.1.1.2. Biological sample source description	Peripheral whole blood
2.1.1.3. Biological sample source organism description	Homo sapiens
2.1.2.2. Environmental sample location	EDTA treated polystyrene test tubes
2.3. Sample treatment description	Erythrocyte lysis, CD14 labelling, 4%PFA fixation, permeabilization, CFTR labelling
2.4. Fluorescence reagent(s) description	Anti-CD14 antibody with PE-Cy7 or APC, secondary antibodies with AF488 or FITC
3.1. Instrument manufacturer	Miltenyi Biotech
3.2. Instrument model	MACSQuant Analyzer
3.3. Instrument configuration and settings	Normal and same detector voltages among samples, optical filters installed Nov 2010
4.1. List-mode data files	<p>*We recommend all authors to submit their data files to http://flowrepository.org and to make them available for the peer-review process. If you have done so, please let us know by inserting the following codes (replace the red text):</p> <p>1) The link for peer-review process: http://flowrepository.org/id/FR-FCM-ZZ85</p> <p>2) The repository identifier: http://flowrepository.org/id/FR-FCM-ZZ85</p>
4.2. Compensation description	Tested and found not to be necessary
4.3. Data transformation details	FCS files analysed with FCS Express v3 software (De Novo Software, Los Angeles, U.S.A.).
4.4.1. Gate description	Based on SSC values and CD14-signal
4.4.2. Gate statistics	Geometrical means of MFI values were used

4.4.3. Gate boundaries



Subjective:

5-10% of gated events below threshold obtained with anti-CFTR antibody preincubated with blocking peptide.

Notes

Feel free to use more space than allocated.

You can embed graphics/figures in this document, if needed.

Please make sure to save the document in Microsoft Word version 2003 or older, before uploading to ScholarOne Manuscripts. When uploading this checklist to ScholarOne Manuscripts, please choose the "Supplementary Material for Review" category.

Please note that if your paper is accepted, the checklist will be published as an Online Supporting Information.

For any questions, please contact the Cytometry Part A editorial office at Cytometry@wiley.com.